title: [Comparison of combined immunization schemes influence on anti-HBs of babies born to mothers with high-load hepatitis B virus infection].
abstract: OBJECTIVE
  To compare the various combined immunization schemes available for treatment of babies born to mothers with high-load hepatitis B virus (HBV) infection.
  
  
  METHODS
  A total of 118 mothers with HBV infection status of hepatitis B surface antigen-positive (HBsAg+), hepatitis B e antigen-positive (HBeAg+) and HBV DNA load of more than 1.0 * 61og10 IU/mL were included in the study. All of the participants' babies received the main-passive immunization therapy according to the wishes of their families. For analysis,the infants were grouped according to the various dosages of the vaccine program (group A: hepatitis B immunoglobulin (HBIG) 200 IU and HBVac 20 mug intramuscular;group B:HBIG 200 IU and HBVac 10 mug intramuscular; group C HBIG 100 IU and HBVac 20 mug intramuscular injection) and times, and followed-up to 7 months of age.All results were statistically analyzed using SPSS software.
  
  
  RESULTS
  All of the infants produced anti-HBs after vaccination.After the HBIG injection schedule was completed in January, the mean concentrations of anti-HBs in groups A, B, and C were 263.56 ± 50.98,231.06 ± 74.07, and 99.23 ± 29.82 mIU/mL respectively;the concentrations were significantly different between groups A and C, and between groups B and C (P < 0.001). In July, the titers of anti-HBs in groups A, B, and C were 788.10 ± 281.96,428.39 ± 347.48, and 708.44 ± 315.69 mIU/mL respectively; the concentrations were significantly different between groups A and B, and between groups B and C (P < 0.05).
  
  
  CONCLUSIONS
  AdminisWation of the hepatitis B vaccine combined with HBIG at birth can achieve immune protection for babies born to highly viremic mothers. In January, the HBIG dosage of 200 IU was more reliable than 100 IU. The hepatitis B 20 tg dose vaccine was safe and effective.
authors.affiliation: Deparment of Obstetrics and Gynecology, Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
authors.forename: Cuimin
authors.initials: C
authors.lastname: Wang
authors.forename: Guorong
authors.initials: G
authors.lastname: Han
authors.forename: Hongxiu
authors.initials: H
authors.lastname: Jiang
authors.forename: Naiying
authors.initials: N
authors.lastname: Kan
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Jinmei
authors.initials: J
authors.lastname: Shi
mesh_terms: D006509:Hepatitis B; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D006515:Hepatitis B virus; D006801:Humans; D007114:Immunization; D007136:Immunoglobulins; D007223:Infant; D009035:Mothers; D012698:Serologic Tests; D017778:Vaccines, Combined; D019562:Viral Load
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D007136:Immunoglobulins; D017778:Vaccines, Combined; C038767:immunoglobulin B; C045213:hepatitis B hyperimmune globulin